ABSTRACT
-
Background/Aims
A clinical unmet need persists for medications capable of modulating the progression of primary sclerosing cholangitis (PSC). This study aimed to assess the clinical feasibility of HK-660S (beta-lapachone) in PSC.
-
Methods
In this multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 trial, participants were assigned in a 2:1 ratio to receive either 100 mg of HK-660S or a placebo twice daily for 12 weeks. The primary outcomes were the reduction in serum alkaline phosphatase (ALP) levels and the percentage of participants showing improvements in PSC severity, as determined by magnetic resonance cholangiopancreatography with the Anali score. Secondary endpoints included changes in liver stiffness and adverse events.
-
Results
The analysis included 21 patients, 15 receiving HK-660S, and six receiving a placebo. Improvements in the Anali score were observed in 13.3% of the HK-660S group, with no improvements in the placebo group. HK-660S treatment resulted in a 15.2% reduction in mean ALP levels, compared to a 6.6% reduction in the placebo group. A stratified ad-hoc analysis based on baseline ALP levels showed a statistically significant response in the HK-660S group among those with ALP levels greater than twice the upper limit of normal, with a 50% responder rate (P=0.05). Additionally, 26.7% of the HK-660S group showed improvements in the enhanced liver fibrosis score, with no improvements in the placebo group. HK-660S was generally well tolerated.
-
Conclusions
HK-660S is well tolerated among patients with PSC and may improve bile duct strictures, decrease serum ALP levels, and reduce liver fibrosis (
cris.nih.go.kr, Number KCT0006590).
-
Keywords: Primary sclerosing cholangitis; Lapachone; Cholangiopancreatography, magnetic resonance; Alkaline phosphatase; Nicotinamide adenine dinucleotide
Study Highlights
• The treatment options for PSC are limited, and current therapeutic approaches mainly focus on symptom management and complications rather than disease progression alterations.
• This multicenter, randomized, controlled trial provided the first clinical evidence assessing the feasibility of HK-660S in patients with PSC. HK-660S was well tolerated and suggested potential clinical benefits.
• HK-660S appears to be a promising treatment option for PSC, evidenced by consistent ALP level reductions and improvements in imaging.
Graphical Abstract
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease of unknown cause, marked by chronic fibrosis and inflammation that leads to the destruction and narrowing of the bile ducts [
1]. This condition increases the risk for cholangiocarcinoma, cirrhosis, and colorectal cancer, making liver transplantation the only end-stage treatment option. Symptoms of PSC vary widely, from asymptomatic to severe, underscoring the urgent need for therapeutic advances [
2].
Several drugs are in development for PSC, but challenges such as lack of efficacy or severe side effects have led to the discontinuation of some, like obeticholic acid (OCA) and cilofexor, despite their initial promise as farnesoid X receptor (FXR) agonists [
3]. The development of OCA for PSC is uncertain after a phase 2 study, and cilofexor was discontinued during phase 3 [
4,
5]. Both drugs were associated with a high incidence of pruritus in treated patients [
3,
6], indicating challenges for future FXR agonist-based therapies.
Treatment strategies exploring PPAR-delta or PPAR-alpha/delta targeting for reducing bile acid synthesis have shown potential. Activation of these pathways increases fibroblast growth factor 19 (FGF19) and FGF21 expression, reducing CYP7A1 and bile acid synthesis [
7]. Although Seladelpar, a PPAR-delta agonist, was discontinued during a phase 2 trial for non-alcoholic steatohepatitis due to liver damage concerns [
8], it showed promising results in a phase 3 trial for primary biliary cholangitis (PBC) [
9]. Ursodeoxycholic acid (UDCA), used for supportive care in PSC, has shown mixed results. Low doses of UDCA improve serum alkaline phosphatase (ALP) levels but do not improve liver histology or survival rates, whereas high doses of UDCA increase the risks of adverse reactions and colorectal neoplasms [
10,
11], necessitating further research on its efficacy. In 2017, a phase 2 trial of norUDCA showed promising results, including a dose-dependent reduction in ALP levels and comparable adverse events to the placebo group [
12]. However, phase 3 trials of norUDCA for PSC have not been published yet.
Overall, while multiple potential therapeutic avenues are being explored, none have yet been definitively successful, and liver transplantation remains the only curative option for advanced disease. Ongoing clinical trials and research are crucial for finding effective treatments for PSC.
Based on a previous
in vivo study using a 3,5-diethoxycarbonyl-1,4-dihydrocollidine-induced PSC mouse model, beta-lapachone effectively inhibited key features of PSC pathogenesis. It reduced aspartate aminotransferase (AST) and ALP levels and improved pathogenic characteristics, such as inflammation (IL-1β, TNF-α, and TGF-β1) and fibrosis (Col1a2). Furthermore, beta-lapachone significantly decreased liver tissue fibrosis [
13]. Additionally, beta-lapachone was shown to stimulate the expression of genes related to NAD synthesis and Abcb4, which contributed to improved mitochondrial stability and overall amelioration of PSC pathogenesis [
13].
HK-660S, a synthetic beta-lapachone compound, explicitly targets the NAD(P)H quinone dehydrogenase 1 (NQO1) enzyme, enhancing intracellular NAD+ levels [
14]. This elevation activates the NAD-dependent sirtuin family (SIRT1-SIRT7), which is crucial for regulating energy metabolism. Notably, SIRT1 boosts AMP-activated protein kinase by influencing liver kinase B1, serving as an energy sensor.
The effect of HK-660S on sirtuins results in anti-inflammatory and anti-fibrotic actions. Specifically, activated SIRT1 curtails inflammation by reducing the activity of key transcription factors, such as nuclear factor-kB and activator protein 1 [
15], and combats liver fibrosis by inhibiting hepatic stellate cells [
16]. SIRT1 reduces fibrotic and inflammatory liver damage caused by cholestatic liver injury in mice fed cholic acid [
17], with SIRT6 also reported to protect against such damage by deacetylating estrogen-related receptor γ, affecting bile secretion.
Initial phase 1 trials found HK-660S well tolerated with favorable pharmacokinetics in healthy volunteers [
18,
19], leading to a phase 2 study to evaluate its efficacy and safety in treating patients with PSC.
MATERIALS AND METHODS
Study design and participants
The present study was designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2a, proof-of-concept study (
Supplementary Fig. 1).
The study protocol was approved by the Korean Ministry of Food and Drug Safety and institutional review boards. All patients provided written informed consent before study participation. The study was conducted according to Good Clinical Practice guidelines of the International Council for Harmonization and the Declaration of Helsinki. The study is registered with cris.nih.go.kr (KCT0006590). All authors had access to the study data and reviewed and approved the final manuscript.
PSC patients aged >17 years were diagnosed according to the following criteria: i) serum ALP levels >1.5 times the upper limit of normal (ULN) at screening; ii) patients previously diagnosed with PSC due to multifocal bile duct involvement, as determined by magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography, and who had baseline MRCP images within 6 months of screening. Critical exclusion criteria included chronic liver diseases other than PSC, obstacles to MRCP implementation, and any clinically significant cardiovascular diseases. Furthermore, patients with PSC unsuitable for participation in the study at the investigator’s discretion, those administered herbal medicine to improve fatty liver disease within 2 weeks of screening, alanine aminotransferase (ALT) or AST >10 times the ULN, and serum creatinine ≥2 mg/dL were excluded. Participants with chronic liver diseases other than PSC, including non-alcoholic fatty liver disease, viral chronic hepatitis, alcoholic liver disease, PBC, biliary obstruction, autoimmune hepatitis, hemoglobin deposition, Wilson’s disease, α-1 antitrypsin deficiency, thyroid diseases, autoimmune diseases, and medication history for steatohepatitis within five times the half-life of the respective drug before screening were also excluded. All medication possibly related to PSC except low-dose UDCA, azathioprine, and prednisone were prohibited.
Randomization and masking
The randomization codes for this clinical study were created using SAS® (version 9.4; SAS Institute Inc., Cary, NC, USA) by a statistician not directly related to this study, in order to assign the participants to the HK-660S or placebo group in a 2:1 ratio by stratified block randomization method using the NQO1 genotypes (T/T, C/T, C/C type) as a stratification factor. The sponsor packed the study drugs according to the randomization codes and distributed the study drugs to clinical sites prior to the start of the clinical study. Participants who met the inclusion/exclusion criteria were assigned to each treatment group in the order of enrollment according to the randomization codes using the interactive web response system.
To maintain the blinding, the placebo has the same formulation and appearance as the investigational product to make them visually indistinguishable. Furthermore, the study drugs were indistinguishable by taste, appearance, scent, and color.
Procedures
After participants voluntarily consented to participate in the clinical study, those who met the inclusion/exclusion criteria were evaluated through a 5-week screening period. HK-660S or placebo were provided as a 100 mg tablet, which was administered orally twice a day before morning and evening meals. The participants visited the study sites every 4 weeks during the treatment period. After treatment, safety follow-up was conducted for an additional 4 weeks. Study drugs were provided for 12 weeks in a double-blind manner.
Outcomes
The primary endpoints were 1) the percentage of patients who showed improvement in PSC severity, as assessed by the Anali score in MRCP at week 12, and 2) the change in serum ALP levels 12 weeks from baseline. The Anali scores were calculated as follows: Anali score=Without gadol inium: (1×Di latat ion of intrahepat ic duct)+ (2×Dysmorphy)+(1×Portal hypertension)+With gadolinium: (1×Dysmorphy)+(1×Parenchymal enhancement heterogeneity) [MRCP Anali score range: 0 to 7, intrahepatic bile duct dilatation: 0 (≤3 mm), 1 (<3 mm and <5 mm), 2 (≥5 mm), Dysmorphy, Portal hypertension: 0 (absent), 1 (present)].
The scores are graded and totaled from 0 to 7 and evaluated on a separate form (evaluation form). Improvement in the severity of PSC was defined as a decrease of 1 or lower in the MRCP Anali score. After viewing the MRCP videos for each participant, an independent blinded radiologist graded the Anali score [
20]. To address the issues in MRCP evaluation, such as poor inter- and intra-observer agreement and variability in technique between exams [
21], this clinical trial employed two independent radiologists at a central imaging lab who assessed MRCP videos independently. If there was a disagreement in the Anali score between two radiologists, an independent adjudicator made the final decision on the Anali score.
Secondary efficacy endpoints included: 1) the percentage of participants who showed improvement of bile duct strictures in MRCP, 2) liver elasticity values obtained from vibration controlled transient elastography (VCTE), 3) hepatic function and biochemistry tests such as ALT, AST, gamma-glutamyl transferase (γ-GT), and total bilirubin, 4) fibrosis as assessed by the enhanced liver fibrosis (ELF) score and serum C4 (7α-hydroxy-4-cholesten-3-one) levels.
Exploratory endpoints included: 1) lipid profiles such as total cholesterol, triglycerides, free fatty acid, LDL-C, and HDL-C; 2) HOMA-IR; 3) body mass index (BMI), waist circumference, and fatigue severity scale; 4) PSC-related biomarkers such as CK-18, CCL-2, CCL-5, hs-CRP, CRP, FGF21, and GDF15; 5) inflammatory cytokines including TNF-α, TGF-β, IL-6, and adiponectin, and 6) mechanism-related biomarkers (lactate, pyruvate, and lactate/pyruvate ratio). The medication adherence was assessed by patients bringing their clinical medication bottles to each regular visit, during which the pharmacist confirmed the amount of medication remaining. Safety was monitored by evaluating adverse events and serious adverse events (SAEs).
Statistical analysis
A study size of at least 12 participants in the treatment group was determined without formal statistical hypothesis testing according to the precedent [
22]. A 2:1 randomization ratio was used to reduce the exposure rate to placebo for ethical reasons. Thus, considering a drop-out rate of approximately 20%, 25 participants were targeted for enrollment, with a minimum of 14 randomized to HK-660S and seven randomized to placebo.
The efficacy analysis was performed for both the full analysis set (FAS) and the per-protocol set (PPS). However, the interpretation of results for the final efficacy evaluation was based on the FAS. All statistical analyses used SAS® (version 9.4; SAS Institute Inc.). In principle, the sig-nificance test between treatment groups was a two-sided test under a significance level of 10%. Descriptive statistics were presented for continuous variables, and a t-test or Wilcoxon rank sum test was performed to test the difference between groups. For categorical variables, frequency and ratio were given, and a chi-square or Fisher’s exact test was performed to test the difference between groups. When missing values occurred in the efficacy endpoint measurements in the FAS population, the last observation carried forward method was applied. Efficacy endpoints measured only once after the baseline were analyzed using the observed values. For safety and other data, the observed data were analyzed without correction.
A subgroup analysis was performed based on NQO1 genotype stratification. Ad-hoc analyses were performed to identify meaningful clinical data. Specifically, studies were performed for the change in ALP levels based on the following criteria: 1) PSC duration, 2) Inflammatory bowel disease (IBD) diagnosis, 3) baseline ALP > 2 times the ULN, and 4) ALP reduction of 20% or more.
The primary efficacy analysis compared the change in ALP levels between the HK-660S and placebo groups from baseline to week 12, using an analysis of covariance (ANCOVA) model, with treatment as a fixed effect and baseline ALP, age, and BMI as covariates. ANCOVA and repeatedmeasures ANCOVA in a mixed model were used to provide estimates of ALP change from baseline and correspond to a 95% confidence interval (CI) at each visit. Changes from biochemical parameters obtained from the model are reported as least-square mean with standard error (SE) for statistical testing.
RESULTS
Patient population
A total of 23 patients were enrolled and randomized into the placebo (n=7) or treatment group (n=16) as the safety set. One patient from each of the placebo and treatment groups met the exclusion criteria (change in UDCA dosage during the screening period) and was eliminated from the FAS (n=21; placebo, 6; study group, 15). Out of the 21 patients in the FAS, four patients in the treatment group were disqualified owing to medication with prohibited drugs, whereas one patient in the placebo group was disqualified owing to a randomization error. Thus, the PPS (n=16) consisted of five patients in the placebo group and 11 in the study group (
Fig. 1).
Demographics and baseline characteristics resembled those typically observed in patients with PSC (
Table 1). Medication compliance was more than 80% for all patients. Except for two patients, all were concomitantly administered UDCA (with one patient from each group not receiving it). Most patients were administered 900 mg/day or less, whereas two patients in the HK-660S group exceeded 900 mg/day (1,200 and 1,600 mg/day). The range of administered UDCA doses was from 5.0 to 16.9 mg/kg/day.
The primary efficacy analysis in the FAS population showed a favorable improvement rate of PSC severity on the MRCP Anali score in the HK-660S group, with an im-provement rate of 13.3% (90% CI 2.42–36.34) compared to 0% (90% CI 0–39.30) in the placebo group without statistical significance (
Fig. 2A). In the PPS population, the improvement rate of PSC severity in the HK-660S group was 9.1% (90% CI 0.47–36.44) compared with 0% (90% CI 0–45.07) for the placebo group (
Fig. 2B). Both patients with a decrease in Anali scores showed a dilation of the bile duct (baseline-12 weeks-16 weeks; 6-5-5 and 4-3-2) (
Fig. 2C).
In the FAS population, mean ALP levels decreased in the HK-660S treatment group by 78.6±60.35 U/L (vs. 33±24.00 U/L in placebo) after 12 weeks. However, owing to the low sample size, statistical significance could not be derived (
P=0.73; Wilcoxon rank sum test) (
Fig. 3A). In the PPS population, mean ALP levels decreased in the HK-660S treatment group by 148.6±71.43 U/L (vs. 46.8±24.05 U/L in placebo) after 12 weeks (
Fig. 3B).
The HK-660S group showed a decrease of 15.2% in mean ALP levels at 12 weeks compared with 6.6% in the placebo group (
Fig. 3C). An ad-hoc analysis was performed to identify a meaningful response rate to drug treatment. When the patient population was stratified by baseline ALP levels, a statistically significant 50% responder rate (percentage of patients achieving a 20% or greater reduction in ALP levels at 12 weeks from baseline) was observed in patients with a baseline ALP >2 times the ULN and treated with HK-660S (
P=0.05; Fisher’s exact test, significant at a two-tailed α=0.1). This contrasted with the placebo group, where none of the patients showed a reduction in ALP greater than 20%.
The improvement rate of biliary stricture based on MRCP in the FAS population was 26.7% (90% CI 9.7–51.1%) of patients in the HK-660S group showed an improvement, whereas none (90% CI 0–39.3%) of the patients in the placebo group showed improvement (P=0.28). In the PPS population, 27.3% (90% CI 7.9–56.4%) of patients in the HK-660S group showed an improvement, whereas none (90% CI 0–45.1%) of the patients in the placebo group showed improvement (P=0.51).
Liver elasticity also showed improvement. Three patients in the HK-660S group showed improvement from severe (F3) to normal (F0–1), severe to moderate (F2), and moderate to normal. In contrast, one patient in the placebo group worsened from moderate to severe. Regarding the ELF score, four patients (26.7%) in the HK-660S group improved from severe to moderate fibrosis at 12 weeks, compared to none in the placebo.
Although serum AST, ALT, and total bilirubin levels did not show noticeable differences between the treatment and placebo groups, γ-GTP showed decreasing trends in the treatment group (
Supplementary Fig. 2).
Exploratory biomarkers were obtained at baseline and 12 weeks. These included the inflammatory biomarkers TNF-α, TGF-β, IL-6, CCL-2, and CCL-5 (
Supplementary Fig. 3A–
E). Additionally, PSC-related biomarkers, including CK-18, GDF15, and FGF21 were also measured (
Supplementary Fig. 3F–
H). Except for TNF-α, FGF21, and CK-18, other biomarkers showed decreasing trends in the HK-660S treatment group. Most notably, CCL-2 showed a statistically significant decrease (
P=0.04; Wilcoxon rank sum test) in the treatment group.
During the study period, the rate of at least one treatment-emergent adverse event (TEAE) was 42.9% (3/7, nine events) in the placebo group and 62.5% (10/16, 36 events) in the HK-660S group (
Table 2). Most TEAEs were mild to moderate in severity. Adverse drug reactions (ADRs) occurred in 18.8% (3/16, seven events) and were only observed in the HK-660S group. Three patients experienced seven ADRs, including abdominal pain (two instances), abdominal distension, diarrhea, nausea, fatigue, and dizziness. All ADRs were mild in severity except for one instance of moderate diarrhea, which resolved after treatment discontinuation. An SAE was reported for one patient (bacteremia) in the HK-660S group but was assessed as not related to drug treatment. No deaths were reported during the study.
DISCUSSION
PSC remains a challenging condition with limited effective therapeutic options, highlighting the urgent need for new treatments. Specifically, the U.S. National Institutes of Health lists clinical trials such as a study evaluating the safety and efficacy of DUR-928 in subjects with PSC (NCT03394781) and a study on the antimicrobial and immunomodulating effects of oral vancomycin in PSC (NCT01802073) [
23]. Additionally, therapies targeting the gutliver axis, such as antibiotics and integrin blockers like vedolizumab, are being explored due to the association of PSC with inflammatory bowel disease and the gut microbiome (NCT03035058) [
24]. These trials reflect a broad spectrum of therapeutic targets, from immunomodulation and fibrosis inhibition to modification of bile acid metabolism, highlighting the diverse pathophysiological insights that are currently guiding PSC research.
This study shows HK-660S as a potential treatment option, evidenced by significant and consistent ALP reductions. Notably, improvements began by week 4 and persisted, demonstrating its effectiveness in reducing PSC severity. Enhanced imaging techniques, such as MRCP and VCTE, suggested potential improvements in biliary stricture and fibrosis with HK-660S treatment, indicating therapeutic benefits in PSC liver pathology. Furthermore, regarding the ELF score, four patients (26.7%) in the HK-660S group improved from severe to moderate fibrosis at 12 weeks, compared to none in the placebo. However, it is important to note that the observed differences were not statistically significant.
HK-660S and other candidates showed promising results in liver injury biomarkers for PSC. In a clinical trial, norUDCA treatment significantly reduced ALT, AST, γ-GT, and ALP levels; however, SAEs were reported for seven patients in the low dose group [
12]. OCA, a potent FXR agonist, decreased ALP and bilirubin levels in a clinical trial for primary biliary cholangitis [
25,
26]. In the phase 2 clinical study for PSC, OCA reduced ALP levels significantly within 24 weeks, with notable TEAEs related to pruritus [
3]. NGM282, an engineered analog of FGF19, improved ALT, AST, and fibrosis biomarkers, including Pro-C3, and was generally well tolerated [
27]. HK-660S prominently reduced ALP and γ-GT levels while improving fibrosis markers (ELF and VCTE), with most TEAEs related to mild and moderate gastrointestinal symptoms.
In contrast, four types of surrogate endpoints are used in therapeutic trials for PSC: serum biomarkers (such as ALP or ELF score), MRCP, liver elastography, and prognostic scores. Among these, MRCP is a powerful and non-invasive diagnostic method for evaluating bile duct strictures in PSC. Notably, the MRCP Anali score has been shown to correlate strongly with survival outcomes and is a valuable non-invasive prognostic tool for predicting disease progression in patients with PSC [
28-
30]. ALP is also widely used as a surrogate endpoint for both PSC and PBC. However, accumulating evidence indicates significant variability in serum ALP levels, both within and among patients, regardless of treatment. This variability may limit the utility of ALP as the sole surrogate endpoint for demonstrating clinical efficacy in trials [
28]. Therefore, the results of this study, including the structural improvements in PSC severity indicated by the Anali score and the assessment of bile duct strictures by MRCP, provide strong evidence supporting the potential of HK-660S as a treatment option for PSC.
This study had several limitations. First, in the exploratory proof-of-concept study of HK-660S, the sample size was not formally calculated due to its initial clinical application to patients with PSC. In this phase 2a trial, the efficacy analysis was performed for both the FAS and the PPS, but the interpretation of results for the final efficacy evaluation was based on the FAS according to the study protocol. Although the number of participants in the PPS did not reach the predetermined size of 12 per treatment group, the number in the FAS was adequate for the final efficacy evaluation. Moreover, we consider the trend towards decreased ALP levels and improvement in biliary stricture observed on MRCP imaging to be promising indicators of the potential efficacy of HK-660S in treating PSC within the relatively short study period of 12 weeks. The improvement observed in MRCP images was particularly noteworthy. The use of exploratory endpoints is encouraged in PSC studies due to challenges in identifying appropriate study endpoints that adequately measure clinical benefit in PSC. Therefore, this proof-of-concept study for PSC was designed to explore any potential role of HK-660S.
Second, this pilot study would have benefitted from a longer treatment duration, such as 24 weeks, to evaluate cholangiographic changes using its proposed primary endpoint (Anali score) as well as the measurement of additional markers of fibrosis, such as pro-C3. Future confirmatory trials are planned to extend the treatment duration to at least 24 weeks and incorporate statistical sample size calculation, additional fibrosis markers (CCL-24, pro-C3), and prognostic factors (PRESTO, UK-PSC, Mayo-PSC).
Despite the limitations of this study, including the insufficiency to yield statistically significant results owing to the small sample size, subgroup analyses have provided intriguing insights into the differential responses to HK-660S based on patient characteristics. Patients with pre-existing IBD showed improvements in ALP levels, suggesting a potential synergistic effect between HK-660S and the management of IBD. Additionally, patients with baseline ALP levels exceeding twice the ULN showed a more potent reduction in ALP levels, suggesting that HK-660S may be particularly effective in patients with higher baseline ALP values.
In conclusion, in this phase 2a study of patients with PSC, HK-660S 100 mg twice daily over 12 weeks demonstrated promising trends in reducing serum ALP levels and improving biliary stricture on MRCP, although these results were not statistically significant. Moreover, HK-660S was well tolerated and potentially improved liver fibrosis. Its favorable safety profile and potential clinical benefits warrant further investigation in larger trials.
ACKNOWLEDGMENTS
This study was supported by Curome Biosciences Co., Ltd, which was involved in the study design, data collection, analysis, and interpretation of data. D.H.P. is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: RS-2024-00435385).
FOOTNOTES
-
Authors’ contribution
Do Hyun Park contributed to the study design, data collection, data analysis, data interpretation, and the first draft of the manuscript. Woo Hyun Paik and Joo Kyung Park contributed to data collection, data analysis, data interpretation, and the first draft of the manuscript. Moon Jae Chung and Gunn Huh contributed to the data collection and editing of the manuscript. Ce Hwan Park contributed to editing of the manuscript. All authors approved the final manuscript.
-
Conflicts of Interest
Heon Se Jeong and Hee Jin Kim are Curome Biosciences Co., Ltd employees. The other authors disclose no conflicts.
SUPPLEMENTAL MATERIAL
Supplementary material is available at Clinical and Molecular Hepatology website (
http://www.e-cmh.org).
Supplementary Figure 1.
Overall study design. Patients were screened 5 weeks prior to the start of the study. Eligible patients were randomly assigned to either placebo or HK-660S group at a 1:2 ratio. After randomization, baseline measurements were obtained. Patients periodically visited the study sites at 4, 8, and 12 weeks. After the end of treatment, patients underwent a follow-up visit 4 weeks later (16 weeks). D, day; F/U, follow-up.
Supplementary Figure 2.
Absolute changes in ALT, AST, γ-GT, and total bilirubin levels. (A) Absolute change in serum AST throughout the trial. (B) Absolute change in serum ALT throughout the trial. (C) Absolute change in serum γGT throughout the trial. (D) Absolute change in total bilirubin throughout the trial. AST, aspartate transferase; ALT, alanine transferase; γ-GT, gamma-glutamyl transferase.
Supplementary Figure 3.
Change in inflammatory and PSC-related biomarkers at 12 weeks from baseline. (A) TNF-α levels at 12 weeks from baseline. (B) TGF-β levels at 12 weeks. (C) IL-6 levels at 12 weeks. (D) CCL-2 levels at 12 weeks. (E) CCL-5 levels at 12 weeks. (F) CK-18 levels at 12 weeks. (G) GDF15 levels at 12 weeks. (H) FGF21 levels at 12 weeks. *P=0.037, Wilcoxon rank sum test.
Figure 1.Patient disposition. Nine of 32 patients were excluded for the following reasons. Participants who have T/T type as determined by NQO1 genotyping assays (n=5) (exclusion criteria before protocol change), participants who have ALT or AST >5 times the upper limit of normal (ULN) (n=2), serum ALP of <1.5 times the ULN at screening (n=1), and expiration of screening period (n=1). NQO1, NAD(P)H quinone dehydrogenase 1; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FAS, full analysis set; PPS, per protocol set. *Four participants were excluded from the FAS due to the administration of herbal medicine.
Figure 2.(A) Improvement rate of PSC severity based on MRCP Anali scores in the FAS and (B) PPS population. (C) Improvement of biliary strictures after HK-660S treatment in MRCP images. PSC, primary sclerosing cholangitis; MRCP, magnetic resonance cholangiopancreatography; FAS, full analysis set; PPS, per protocol set.
Figure 3.(A, B) Mean change in ALP from baseline and at 4, 8, 12, and 16 weeks (FAS) and (PPS). (C) Percent change in ALP from baseline and responder ad-hoc analysis. ALP, alkaline phosphatase; BL, baseline; FAS, full analysis set; PPS, per protocol set; ULN, upper limit of normal.
Table 1.Baseline demographics and disease characteristics (FAS Population)
Table 1.
|
Characteristic |
Placebo (n=6) |
HK-660S (n=15) |
|
Age, yr |
54.3±22.1 |
43.3±10.4 |
|
≥65 yr |
2 (33.3) |
0 |
|
Sex |
|
|
|
Male |
2 (33.3) |
10 (66.7) |
|
Female |
4 (66.7) |
5 (33.3) |
|
Height (cm) |
163.4±9.1 |
168.7±10.0 |
|
Weight (kg) |
61.6±11.0 |
64.2±14.1 |
|
BMI (kg/m2) |
23.0±3.3 |
22.4±3.7 |
|
WC (cm) |
85.1±7.6 |
82.0±9.2 |
|
PSC duration (yr) |
4.4±3.5 |
5.3±3.6 |
|
Co-morbidity of IBD |
|
|
|
Ulcerative colitis |
2 (33.3) |
7 (46.7) |
|
Crohn’s disease |
0 |
1 (6.7) |
|
ALP (U/L) |
503.3±261.4 |
516.1±336.4 |
|
Total bilirubin (mg/dL) |
1.6±1.3 |
2.2±2.8 |
|
ALT (U/L) |
106.7±115.6 |
82.9±62.2 |
|
AST (U/L) |
91.0±78.5 |
80.4±40.4 |
|
UDCA treatment |
5 (83.3) |
14 (93.3) |
|
NQO1 genotype |
|
|
|
T/T type |
3 (50.0) |
6 (40.0) |
|
C/T type |
3 (50.0) |
6 (40.0) |
|
C/C type |
0 |
3 (20.0) |
|
Baseline Anali score |
4.5 (1–7) |
3.0 (0–6) |
|
Baseline liver stiffness (kPa) |
24.7±16.2 |
14.7±10.3 |
|
Baseline ELF score |
11.4±0.8 |
10.5±1.3 |
Table 2.Summary of TEAEs and ADRs (Safety set population)
Table 2.
|
System organ class preferred term |
Placebo (n=7) |
HK-660S (n=16) |
|
All TEAEs |
3 (42.9) |
10 (62.5) |
|
ADRs |
0 |
3 (18.8) |
|
Gastrointestinal disorders |
|
|
|
Abdominal pain |
0 |
2 (12.5) |
|
Abdominal distension |
0 |
1 (6.3) |
|
Diarrhea |
0 |
1 (6.3) |
|
Nausea |
0 |
1 (6.3) |
|
General disorders |
|
|
|
Fatigue |
0 |
1 (6.3) |
|
Nervous system disorders |
|
|
|
Dizziness |
0 |
1 (6.3) |
|
SAE |
|
|
|
Infections and infestations |
|
|
|
Bacteremia |
0 |
1 (6.3)*
|
Abbreviations
aspartate aminotransferase
endoscopic retrograde cholangiopancreatography
fibroblast growth factor 19
inflammatory bowel disease
magnetic resonance cholangiopancreatography
NAD(P)H quinone dehydrogenase 1
primary biliary cholangitis
primary sclerosing cholangitis
treatment-emergent adverse event
vibration controlled transient elastography
gamma-glutamyl transferase
REFERENCES
- 1. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol 2017;67:1298-1323.
- 2. de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015;21:1956-1971.
- 3. Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, et al.; AESOP Study Investigators. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol 2020;73:94-101.
- 4. Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, et al. Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. Clin Gastroenterol Hepatol 2023;21:1552-1560.e2.
- 5. Trauner M, Levy C, Tanaka A, Goodman Z, Thorburn D, Joshi D, et al. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS). J Hepatol 2023;78(Supplement 1):S12-S13.
- 6. Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 2019;70:788-801.
- 7. Kouno T, Liu X, Zhao H, Kisseleva T, Cable EE, Schnabl B. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. J Biol Chem 2022;298:102056.
- 8. Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, et al. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther 2024;59:186-200.
- 9. Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al.; RESPONSE Study Group. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med 2024;390:783-794.
- 10. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
- 11. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472.
- 12. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, et al.; European PSC norUDCA Study Group. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017;67:549-558.
- 13. Woo SH, Lee SH, Moon SJ, Han J, Seo KS, Lee H, et al. Beta-lapachone ameliorates the progression of primary sclerosing cholangitis pathogenesis in rodent models. Life Sci 2024;337:122342.
- 14. Hwang JH, Kim DW, Jo EJ, Kim YK, Jo YS, Park JH, et al. Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes 2009;58:965-974.
- 15. Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res 2013;67:60-67.
- 16. Li M, Hong W, Hao C, Li L, Wu D, Shen A, et al. SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice. FASEB J 2018;32:500-511.
- 17. Kulkarni SR, Soroka CJ, Hagey LR, Boyer JL. Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. Hepatology 2016;64:2151-2164.
- 18. Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS. Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials. Drug Des Devel Ther 2017;11:3187-3195.
- 19. Lee HW, Seong SJ, Ohk B, Kang WY, Gwon MR, Kim BK, et al. Pharmacokinetic and safety evaluation of MB12066, an NQO1 substrate. Drug Des Devel Ther 2017;11:2719-2725.
- 20. Lemoinne S, Cazzagon N, El Mouhadi S, Trivedi PJ, Dohan A, Kemgang A, et al. Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2019;17:2785-2792.e3.
- 21. Grigoriadis A, Ringe KI, Andersson M, Kartalis N, Bergquist A. Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis. Eur J Radiol 2021;142:109884.
- 22. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 2005;4:287-291.
- 23. Mousavere I, Kalampokis G, Fousekis F, Karayiannis P, Baltayiannis G, Christodoulou D. An overview of recent treatment options for primary sclerosing cholangitis. Ann Gastroenterol 2023;36:589-598.
- 24. Halilbasic E, Fuchs C, Hofer H, Paumgartner G, Trauner M. Therapy of primary sclerosing cholangitis--today and tomorrow. Dig Dis 2015;33 Suppl 2:149-163.
- 25. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al.; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643.
- 26. Nevens F, Lindor KD, Jones DE. Obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:e41.
- 27. Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 2019;70:483-493.
- 28. Tan N, Lubel J, Kemp W, Roberts S, Majeed A. Current therapeutics in primary sclerosing cholangitis. J Clin Transl Hepatol 2023;11:1267-1281.
- 29. Poetter-Lang S, Ba-Ssalamah A, Messner A, Bastati N, Ambros R, Kristic A, et al. Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture. Eur Radiol 2024;34:7632-7644.
- 30. Cazzagon N, Lemoinne S, El Mouhadi S, Trivedi PJ, Gaouar F, Kemgang A, et al. The complementary value of magnetic resonance imaging and vibration-controlled transient elastography for risk stratification in primary sclerosing cholangitis. Am J Gastroenterol 2019;114:1878-1885.
